Body and Mind Inc
CNSX:BAMM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (15.5), the stock would be worth CA$-1.63 (6 640% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | CA$0.03 |
0%
|
| Industry Average | 15.5 | CA$-1.63 |
-6 640%
|
| Country Average | 22 | CA$-2.32 |
-9 381%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
B
|
Body and Mind Inc
CNSX:BAMM
|
3.7m CAD | -0.2 | -0.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.2 |
| Median | 22 |
| 70th Percentile | 36 |
| Max | 116 589.8 |
Other Multiples
Body and Mind Inc
Glance View
Body & Mind, Inc. engages in the provison of medical cannabis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-12-22. The firm has developed the marquis lifestyle, Body and Mind brand in Nevada with penetration into dispensaries and have recently expanded its brand and products to dispensaries in California. The Body and Mind brand appeals to a range of cannabis consumers with products, including flower, oils, extracts, such as wax, live resin and ambrosia, and edibles. In California, the Company, through its subsidiary NMG Cathedral City, LLC (NMGCC), were managing a cannabis business conducting commercial cannabis activity in Cathedral City, California. The firm operates through its subsidiaries, DEP Nevada Inc.; Nevada Medical Group, LLC; NMG Retail, LLC; NMG Long Beach, LLC; NMG Cathedral City, LLC; NMG Chula Vista, LLC; NMG San Diego, LLC; and NMG OH 1, LLC.
